Get the Stockscreener App
883.68
3.71%
-33.97
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $883.68, with a volume of 2.27M.
It is down -3.71% in the last 24 hours and down -2.15% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$917.65
Open:
$900.01
24h Volume:
2.27M
Relative Volume:
0.73
Market Cap:
$789.36B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
39.12
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
-4.68%
1M Performance:
-2.15%
6M Performance:
+7.05%
1Y Performance:
+2.78%
1-Day Range:
$871.73
$900.42
1-Week Range:
$871.73
$930.00
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
883.59 | 819.79B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
227.82 | 555.22B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
198.48 | 355.43B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
189.43 | 298.23B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
112.31 | 283.10B | 64.93B | 18.26B | 12.36B | 7.2751 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly and Co Stock (LLY) Moved Down by 3.03% on Apr 24: What Investors Need To Know - TradingKey
Lilly’s CAR-T devotion; CBER’s next top dog? - Pharma Voice
Eli Lilly Shares Dip Despite Stable Growth in GLP-1 Prescriptions - Yahoo Finance
Radiopharmaceuticals Market Size to Exceed USD 15.21 Billion By 2035 Rising Cancer Cases Boost the Market Demand - GlobeNewswire Inc.
Eli Lilly (LLY) Faces Pressure as Weight Loss Drug Prescriptions Lag Behind Competitor - GuruFocus
LLY stock clings to 200-DMA as sell-off deepens: Retail eyes 'positioning' play ahead of Q1 earnings next week - MSN
LLY Stock Slides Toward Sixth Weekly Loss, But 200-DMA Holds Firm: Is It Setting Up For Earnings Run? - Stocktwits
Eli Lilly shares see Morgan Stanley commentary on Mounjaro, Zepbound scripts - Investing.com Australia
Lilly’s New Obesity Pill Off to Slow Start in Race With Novo - Bloomberg.com
Eli Lilly stock slips despite steady GLP-1 script growth - Investing.com
Ahead of Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued? - Morningstar
Drug company Lilly refuses to list Mounjaro on PBS, says price too low - AFR
Eli Lilly (LLY) Expands Partnership with Hims & Hers - TipRanks
Eli Lilly (LLY) Expands Weight-Loss Offerings Through Hims & Hers Partnership - GuruFocus
BofA raises Hims and Hers stock price target on Lilly partnership - Investing.com
Hims & Hers Adds Lilly GLP-1 Treatments To Lineup – CEO Compares It To Netflix’s Early Days - Stocktwits
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q1 Earnings - TradingView
Hims & Hers stock surges 7% on Eli Lilly partnership expansion - Investing.com
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Community Health (CYH) - The Globe and Mail
AI Models Split on Eli Lilly (LLY) as Growth Strengths Collide With Valuation Risks - TipRanks
Lilly Q1 2026 earnings conference call - Moomoo
3 Healthcare Stocks With the Most Durable Competitive Moats - AOL.com
Eli Lilly Case Over Weight Loss Drugs Kept Mostly Intact - Law360
Why You Should Not Worry About Eli Lilly (LLY) and Company’s Foundayo Treatment Prospects - Insider Monkey
Is Eli Lilly Stock Actually ... Cheap? The Surprising Math Behind Its 2026 Valuation. - The Motley Fool
Bernstein Pounds the Table on Eli Lilly Stock (LLY) Ahead of Q1 Earnings - TipRanks
Parkland School Board members concerned a tax break for Eli Lilly would shortchange district - The Morning Call
Weight Loss Drug Market Resilience Amid Medicare Challenges - GuruFocus
Lilly’s Suit Against Mounjaro Copies Advances in Second Attempt - Bloomberg Law News
Eli Lilly shares trade sideways as Foundayo launches with strong initial prescriptions: weekly report - Traders Union
Medicare delays GLP-1 coverage plan; interim program extended - Seeking Alpha
Here is why Eli Lilly (LLY) is Among the 8 Best Beginner Stocks to Buy Right Now - Insider Monkey
Eli Lilly Stock (LLY) Opinions on Amazon's GLP-1 Program Launch - Moomoo
Insilico launches industry’s first Longevity Board with Lilly exec as chair, Nobel laureate on roster; target-discovery platform gets validation boost - R&D World
Eli Lilly can proceed with lawsuit against telehealth seller of weight-loss drugs - Courthouse News
Rigel Pharmaceuticals to regain rights to ocadusertib after Eli Lilly ends agreement - Investing.com
Eli Lilly’s Kelonia Therapeutics acquisition seen as strategic bet on next-generation CAR-T: analysts - Proactive financial news
Eli Lilly (LLY) Receives Buy Rating Amid Growth Prospects for Ob - GuruFocus
Morgan Stanley reiterates Eli Lilly stock rating on Medicare coverage outlook - Investing.com India
UBS Pounds the Table on Eli Lilly Stock (LLY) After Kelonia Therapeutics Deal - TipRanks
Lilly and Novo Stocks Are Tumbling. How Amazon Is Shaking Up the GLP-1 Game. -- Barrons.com - 富途牛牛
Eli Lilly and Co Stock (LLY) Moved Down by 3.52% on Apr 21: Key Drivers Unveiled - TradingKey
Eli Lilly stock price forecast: $850–$900 range as LLY declines 3.78% - Traders Union
Eli Lilly (LLY) Faces Challenges with Medicare Coverage for Weig - GuruFocus
Why Did Eli Lilly Stock Drop Today? - Yahoo Finance
Eli Lilly Acquires Kelonia Therapeutics for Up to $7 Billion - GuruFocus
UBS reiterates Eli Lilly stock Buy rating after Kelonia deal - Investing.com
UBS reiterates Eli Lilly stock Buy rating after Kelonia deal By Investing.com - Investing.com India
UnitedHealth, Eli Lilly among market cap stock movers on Tuesday - Investing.com
Guggenheim Adjusts Price Target on Eli Lilly to $1,183 From $1,163, Maintains Buy Rating - marketscreener.com
Eli Lilly backs crackdown on fake Mounjaro in Gurugram, flags safety risks - Business Standard
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):